Literature DB >> 26992744

[Cochrane Corner: Intra-aortic balloon pump in patients with cardiogenic shock following myocardial infarction].

Daniel Caldeira1, Hélder Pereira2, João Costa3, António Vaz-Carneiro4.   

Abstract

Improvement of hemodynamic parameters is the rationale for the use of intra-aortic balloon pump counterpulsation (IABP) in patients with cardiogenic shock following acute myocardial infarction (MI). This Cochrane systematic review evaluated the impact of this intervention in reducing mortality. Seven randomized controlled trials with a total of 790 patients were included (four using medical therapy as a comparator, and three comparing IABP with other ventricular assist devices). IABP did not reduce mortality in either the short or long term. Therefore, the systematic use of IABP in patients with cardiogenic shock following MI cannot be recommended.
Copyright © 2015 Sociedade Portuguesa de Cardiologia. Published by Elsevier España. All rights reserved.

Entities:  

Keywords:  Balão intra‐aórtico; Cardiogenic shock; Choque cardiogénico; Dispositivo de assistência ventricular; Enfarte agudo do miocárdio; Intra‐aortic balloon pump; Left ventricular assist device; Myocardial infarction

Mesh:

Year:  2016        PMID: 26992744     DOI: 10.1016/j.repc.2015.09.013

Source DB:  PubMed          Journal:  Rev Port Cardiol        ISSN: 0870-2551            Impact factor:   1.374


  1 in total

1.  Thrombus aspiration in patients with ST-elevation myocardial infarction: results of a national registry of interventional cardiology.

Authors:  Hélder Pereira; Daniel Caldeira; Rui Campante Teles; Marco Costa; Pedro Canas da Silva; Vasco da Gama Ribeiro; Vítor Brandão; Dinis Martins; Fernando Matias; Francisco Pereira-Machado; José Baptista; Pedro Farto E Abreu; Ricardo Santos; António Drummond; Henrique Cyrne de Carvalho; João Calisto; João Carlos Silva; João Luís Pipa; Jorge Marques; Paulino Sousa; Renato Fernandes; Rui Cruz Ferreira; Sousa Ramos; Eduardo Infante Oliveira; Manuel de Sousa Almeida
Journal:  BMC Cardiovasc Disord       Date:  2018-04-24       Impact factor: 2.298

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.